首页> 外文期刊>DMW: Deutsche Medizinische Wochenschrift >Comparison of extracorporeal liver assist devices - Albumin dialysis versus plasma exchange - In acute-on-chronic liver failure [Vergleich extrakorporaler Leberunterstützungsverfahren - Albumin-Dialyse versus Plasmaaustausch - bei akut-auf-chronischem Leberversagen]
【24h】

Comparison of extracorporeal liver assist devices - Albumin dialysis versus plasma exchange - In acute-on-chronic liver failure [Vergleich extrakorporaler Leberunterstützungsverfahren - Albumin-Dialyse versus Plasmaaustausch - bei akut-auf-chronischem Leberversagen]

机译:体外肝辅助装置的比较-白蛋白透析与血浆置换-急性慢性肝衰竭[体外肝支持方法的比较-白蛋白透析与血浆置换-急性慢性肝衰竭]

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Aim: Extracorporeal liver assist devices are besides causal and symptomatic approaches important therapeutic options in acute-on-chronic (AOC) liver failure. In this retrospective analysis, albumin dialysis was compared to therapeutic plasma exchange (TPA) under various aspects. Patients and Methods: Data from 20 patients per group (10 women, 10 men in each group, mean age 51 ± 12,6 years and 48,2 ± 15,2 years, respectively) treated over a period of 3 months were analyzed. During the first treatment, 5 sessions of dialysis were performed (week 1) for both procedures, 3 more sessions were completed in the second and in the third week each. Data were acquired on days 1, 8, 13, 20, 28 and 90. Results: After 28 days, 13 out of 20 patients following albumin dialysis and 7 out of 20 patients following plasma exchange had survived (p = 0,11). After 90 days, 10 patients following albumin dialysis and 5 patients following plasma exchange were alive (p = 0,19). Degree of hepatic encephalopathy (HE) had not improved significantly. Rates of complication (infections, bleeding or system clotting) were similar under both procedures. Conclusion: Extracorporeal liver assist devices can be considered equally well as a therapeutic option in acute-on-chronic liver failure. Differences in 90-day survival were not observed in our study.
机译:背景与目的:体外肝辅助装置是除因果疗法和对症疗法外,对于慢性慢性肝衰竭(AOC)的重要治疗选择。在此回顾性分析中,在各个方面将白蛋白透析与治疗性血浆置换(TPA)进行了比较。患者和方法:分析了每组20例患者(每组10例女性,每组10例男性,平均年龄分别为51±12.6岁和48,2±15.2岁)在3个月内治疗的数据。在第一次治疗期间,两种方法均进行了5次透析(第1周),第二次和第三周分别完成了3次透析。在第1、8、13、20、28和90天获得了数据。结果:28天后,白蛋白透析后20名患者中有13名存活,血浆置换后20名患者中有7名存活(p = 0.11)。 90天后,白蛋白透析后10例患者和血浆置换后5例患者还活着(p = 0,19)。肝性脑病(HE)的程度没有明显改善。两种手术的并发症发生率(感染,出血或系统凝结)相似。结论:体外肝辅助装置可被视为治疗慢性慢性肝功能衰竭的一种选择。在我们的研究中未观察到90天生存率的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号